Fonds de solidarité FTQ invests $4 mln in biotherapeutics startup Zymeworks
The Fonds de solidarité FTQ has made a $4 million equity investment in Zymeworks Inc, a developer of best-in-class protein therapeutics for the treatment of cancer, autoimmune and inflammatory diseases. Based in Vancouver, the company has significant research activities in Québec. It is currently developing several antibody therapeutics in the field of oncology with anticipated IND filings beginning in 2016. Established in 2003, Zymeworks is also backed by Advanced Biotechnologies Venture Fund and CTI Life Sciences Fund. Earlier this year, the company announced it had raised $17.3 million in funding from a mix of new and existing investors.
19 December 2014•4 mins read
